PTGX – Protagonist Therapeutics Inc
PTGX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
13.44
Margin Of Safety %
-32
Put/Call OI Ratio
0.41
EPS Next Q Diff
2.1
EPS Last/This Y
4.82
EPS This/Next Y
-3.21
Price
103.75
Target Price
112.69
Analyst Recom
1.23
Performance Q
23.25
Upside
-125.6%
Beta
2.12
Ticker: PTGX
16 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | PTGX | 97.46 | 0.09 | 0.14 | 6496 |
| 2026-03-10 | PTGX | 97.14 | 0.09 | 0.07 | 6460 |
| 2026-03-11 | PTGX | 96.5 | 0.09 | 5.35 | 6464 |
| 2026-03-12 | PTGX | 95.53 | 0.13 | 0.22 | 6732 |
| 2026-03-13 | PTGX | 95.42 | 0.13 | 0.22 | 6732 |
| 2026-03-17 | PTGX | 97.28 | 0.14 | 0.70 | 6860 |
| 2026-03-18 | PTGX | 97.11 | 0.16 | 0.26 | 7450 |
| 2026-03-20 | PTGX | 98.94 | 0.24 | 0.07 | 7646 |
| 2026-03-25 | PTGX | 104.36 | 0.18 | 0.11 | 6232 |
| 2026-03-26 | PTGX | 102.05 | 0.18 | 4.21 | 6246 |
| 2026-03-27 | PTGX | 99.73 | 0.20 | 1.30 | 6328 |
| 2026-03-30 | PTGX | 99.88 | 0.21 | 0.06 | 6399 |
| 2026-03-31 | PTGX | 104.6 | 0.21 | 0.14 | 6432 |
| 2026-04-01 | PTGX | 103.74 | 0.22 | 0.03 | 6376 |
| 2026-04-06 | PTGX | 102.94 | 0.41 | 0.00 | 7379 |
| 2026-04-07 | PTGX | 103.66 | 0.41 | 0.00 | 7360 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
16 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | PTGX | 96.72 | -202.4 | - | 2.75 |
| 2026-03-10 | PTGX | 97.10 | -202.4 | - | 2.75 |
| 2026-03-11 | PTGX | 96.48 | -202.4 | - | 2.75 |
| 2026-03-12 | PTGX | 95.45 | -202.4 | - | 2.75 |
| 2026-03-13 | PTGX | 92.37 | -202.4 | - | 2.75 |
| 2026-03-17 | PTGX | 97.24 | -202.4 | - | 2.75 |
| 2026-03-18 | PTGX | 97.14 | -202.4 | - | 2.75 |
| 2026-03-19 | PTGX | 101.67 | -202.4 | - | 2.75 |
| 2026-03-20 | PTGX | 98.90 | -202.4 | - | 2.75 |
| 2026-03-23 | PTGX | 98.47 | -202.4 | - | 2.75 |
| 2026-03-24 | PTGX | 100.39 | -244.3 | - | 2.77 |
| 2026-03-25 | PTGX | 104.19 | -244.3 | - | 2.77 |
| 2026-03-26 | PTGX | 102.06 | -244.3 | - | 2.77 |
| 2026-03-27 | PTGX | 98.84 | -244.3 | - | 2.77 |
| 2026-03-30 | PTGX | 99.81 | -244.3 | - | 2.77 |
| 2026-03-31 | PTGX | 105.49 | -244.3 | - | 2.77 |
| 2026-04-01 | PTGX | 103.68 | -244.3 | - | 2.77 |
| 2026-04-02 | PTGX | 103.72 | -244.3 | - | 2.77 |
| 2026-04-06 | PTGX | 102.96 | -244.3 | - | 2.77 |
| 2026-04-07 | PTGX | 103.75 | -244.3 | - | 2.77 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | PTGX | -5.60 | 1.96 | 14.08 |
| 2026-03-10 | PTGX | -5.60 | 1.96 | 14.08 |
| 2026-03-11 | PTGX | -5.60 | 1.96 | 13.66 |
| 2026-03-12 | PTGX | -5.60 | 1.96 | 13.66 |
| 2026-03-13 | PTGX | -5.60 | 1.96 | 13.66 |
| 2026-03-18 | PTGX | -5.60 | 2.00 | 13.66 |
| 2026-03-19 | PTGX | -5.60 | 2.00 | 13.66 |
| 2026-03-20 | PTGX | -5.60 | 2.00 | 13.66 |
| 2026-03-23 | PTGX | -5.60 | 2.00 | 13.66 |
| 2026-03-24 | PTGX | -5.60 | 2.00 | 13.66 |
| 2026-03-25 | PTGX | -5.51 | 2.00 | 13.44 |
| 2026-03-26 | PTGX | -6.77 | 2.00 | 13.44 |
| 2026-03-27 | PTGX | -6.77 | 2.00 | 13.44 |
| 2026-03-30 | PTGX | -8.20 | 2.02 | 13.44 |
| 2026-03-31 | PTGX | -8.20 | 2.02 | 13.44 |
| 2026-04-01 | PTGX | -8.20 | 2.02 | 13.44 |
| 2026-04-02 | PTGX | -8.20 | 2.02 | 13.44 |
| 2026-04-06 | PTGX | -8.20 | 2.02 | 13.44 |
| 2026-04-07 | PTGX | -8.20 | 2.02 | 13.44 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.69
Avg. EPS Est. Current Quarter
-0.65
Avg. EPS Est. Next Quarter
1.41
Insider Transactions
-8.2
Institutional Transactions
2.02
Beta
2.12
Average Sales Estimate Current Quarter
16
Average Sales Estimate Next Quarter
143
Fair Value
70.27
Quality Score
24
Growth Score
32
Sentiment Score
98
Actual DrawDown %
3.8
Max Drawdown 5-Year %
-85.8
Target Price
112.69
P/E
Forward P/E
PEG
P/S
143.85
P/B
10.56
P/Free Cash Flow
118.05
EPS
-2.04
Average EPS Est. Cur. Y
2.77
EPS Next Y. (Est.)
-0.43
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-282.83
Relative Volume
0.97
Return on Equity vs Sector %
-48.6
Return on Equity vs Industry %
-32.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
◆
PTGX
Healthcare
$103.75
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
10/25
Volume
7/15
Valuation
4/20
TP/AR
4/10
Options
7/10
RSI
61.4
Range 1M
72.1%
Sup Dist
2%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
6/25
Growth
12/30
Estimates
2/20
Inst/Vol
9/15
Options
7/10
EPS Yr
257.6%
EPS NY
-120.9%
52W%
92.9%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-15.9% upside
Quality
6/30
Valuation
1/30
Growth
7/25
Stability
8/10
LT Trend
1/5
Upside
-15.9%
Quality
24
MoS
-32%
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 132
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX
Latest News
—
Caricamento notizie per PTGX…
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading